Benchmark raises Harvard Bioscience stock price target on revenue beat
Benchmark raised its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00 and kept a Speculative Buy rating after Q2 results. Q2 revenue was $22.7M, above guidance and consensus. Full-year 2026 revenue growth guidance was lifted to 3% to 5%. Adjusted gross margin target was lowered to 57% to 59%.
How this was made
The 30-second read
Why it matters
The key tradable inputs are the raised full-year revenue growth range, the updated margin and EBITDA targets, and the analyst’s new $7.50 price target based on a 0.6x NTM revenue multiple.
Market read
Traders may reassess HBIO’s valuation and near-term expectations given the revenue beat, raised growth guidance, and a fresh analyst target update.
What to watch
The gross margin target was lowered (57% to 59% vs prior 58% to 60%), so the valuation rerating may be sensitive to execution on cost discipline and Project Viking savings by 2027.
Background
Benchmark maintained a Speculative Buy rating and updated its valuation after Harvard Bioscience reported Q2 results and issued updated 2026 guidance.
Ticker impact
Benchmark raised HBIO’s price target to $7.50 after Q2 revenue beat guidance and the company lifted 2026 revenue growth guidance to 3% to 5%.
Likely modest positive bias for HBIO as traders price in the raised revenue growth range and margin/EBITDA targets.
The article provides concrete Q2 results, raised full-year revenue guidance, and a new analyst price target, but it is still an analyst action rather than a new company filing or contract award.
Market effects
Supports sentiment for small-cap life-science tools/biotech instrumentation names tied to cellular and molecular workflows.
No direct regional contagion beyond mention of Americas and Asia-Pacific growth rates.
Limited global read-through; mostly company-specific guidance and analyst valuation update.
Counterpoint
Despite the revenue beat and higher guidance, the company is still forecast to be unprofitable in fiscal 2026, which can cap upside if margins or EBITDA conversion disappoint.
Key entities
- companyHarvard Bioscience Inc.
NASDAQ-listed life-science tools company reporting Q2 results and updated 2026 guidance; subject of the analyst price-target change.
- analyst_firmBenchmark
Raised HBIO’s price target to $7.50 from $6.00 while keeping a Speculative Buy rating.
